Active Biotech AB: Interim report January – June 2019
August 8, 2019
News
Active Biotech has entered into an agreement regarding sale of the Company’s property – extraordinary general meeting on April 4, 2019
March 13, 2019
Active Biotech has received an indicative bid for the property in Lund – the Board is positive
February 1, 2019
Active Biotech provides updated information about the company’s financial position
December 10, 2018
New data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference HSG 2018
November 8, 2018
<\span>
Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at “European Huntington’s Disease Network (EHDN) plenary meeting 2018”
September 13, 2018